Roche Launches Vabysmo® (Faricimab), The First And Only Bispecific Monoclonal Antibody For The Eye, To Treat Two Leading Causes Of Vision Loss
•Vabysmo targets and inhibits two disease pathways that cause neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME) •Vabysmo’s revolutionary dual-pathway mechanism of action (MoA) neutralises angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) to restore vascular stability for patients living with nAMD and DME •Vabysmo is the only injectable eye medicine…
